Powder compositions for generating cross-linked protein foams and methods of using thereof
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10596194-B2
Publication Date
2020-03-24
Expiration Date
Abstract
In one embodiment, the present invention provides a composition, wherein the composition is a porous scaffold, wherein the pores of the scaffold are from 2 to 500 microns, the composition comprising: a) a cross-linkable protein selected from the group consisting of collagen and gelatin; b) a cross-linker which induces cross-linking of the cross-linkable protein; and c) a liquid.
Core Innovation
The invention relates to porous scaffold compositions formed as a closed-cell foam. The composition includes cross-linkable gelatin, a cross-linker, and a liquid, and the scaffold has a pore size from 2 to 500 microns. The cross-linkable gelatin is introduced as a hygroscopic gelatin powder having a particle size between 5 to 200 microns, and it is present in the composition in a range of 0.5 wt % to 25 wt %.
In one embodiment, the cross-linker is a transglutaminase that induces cross-linking of the cross-linkable gelatin within the porous closed-cell foam scaffold. The formulation constrains the transglutaminase in the range of 0.0001 wt % to 2 wt %, while retaining the pore size from 2 to 500 microns and the hygroscopic gelatin powder particle size between 5 to 200 microns.
The invention addresses tissue-related problems associated with treating tissue defects and sealing tissue using porous foam/scaffold compositions. The compositions are provided in contexts where they are delivered or formed in situ to support adhesion to tissue and to enable functional outcomes in relation to tissue sealing and defect treatment.
Claims Coverage
The independent claim coverage comprises two independent claim families describing closed-cell foam porous scaffold compositions with controlled pore size and constrained formulations of hygroscopic cross-linkable gelatin powder, a cross-linker, and a liquid. Across the independent claims, the inventive features are governed by pore size (2–500 microns) and gelatin and cross-linker content ranges, with an additional independent claim specifying transglutaminase as the cross-linker.
Porous closed-cell foam scaffold with constrained pore size and components
A composition comprising a closed-cell foam that comprises cross-linkable gelatin, a cross-linker, and a liquid, where the composition is a porous scaffold having a pore size from 2 to 500 microns; the cross-linkable gelatin is introduced as a hygroscopic gelatin powder having a particle size between 5 to 200 microns; the cross-linkable gelatin is present in the composition in the range of 0.5 wt % to 25 wt %; and the cross-linker is present in the composition in the range of 0.0001 wt % to 2 wt %.
Transglutaminase-induced cross-linked gelatin in a closed-cell foam scaffold
A composition comprising a closed-cell foam that comprises cross-linkable gelatin, a transglutaminase which induces cross-linking of the cross-linkable gelatin, and a liquid, where the composition is a porous scaffold having a pore size from 2 to 500 microns; the cross-linkable gelatin is introduced as a hygroscopic gelatin powder having a particle size between 5 to 200 microns; the cross-linkable gelatin is present in the composition in the range of 0.5 wt % to 25 wt %; and the transglutaminase is present in the composition in the range of 0.0001 wt % to 2 wt %.
Together, the independent claims require a closed-cell foam porous scaffold with pore size 2–500 microns, hygroscopic cross-linkable gelatin powder particle size 5–200 microns, gelatin content 0.5–25 wt %, and cross-linker content 0.0001–2 wt %, with one independent claim specifically requiring a transglutaminase cross-linker that induces cross-linking of the gelatin.
Stated Advantages
Documented Applications
Treating tissue defects, including wounds and bone defects, using the porous scaffold composition delivered or formed in situ.
Sealing tissues, including use as a GI sealant and as a surgical sealant/hemostasis.
Reducing lung volume in emphysema via fibroblast attachment/collagen synthesis as described in the document.
Acting as bulking agents for urinary incontinence and fecal incontinence as described in the document.
Interested in licensing this patent?